Literature DB >> 18179835

Welfarism vs. extra-welfarism.

Werner B F Brouwer1, Anthony J Culyer, N Job A van Exel, Frans F H Rutten.   

Abstract

'Extra-welfarism' has received some attention in health economics, yet there is little consensus on what distinguishes it from more conventional 'welfarist economics'. In this paper, we seek to identify the characteristics of each in order to make a systematic comparison of the ways in which they evaluate alternative social states. The focus, though this is not intended to be exclusive, is on health. Specifically, we highlight four areas in which the two schools differ: (i) the outcomes considered relevant in an evaluation; (ii) the sources of valuation of the relevant outcomes; (iii) the basis of weighting of relevant outcomes and (iv) interpersonal comparisons. We conclude that these differences are substantive.

Mesh:

Year:  2007        PMID: 18179835     DOI: 10.1016/j.jhealeco.2007.07.003

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  57 in total

1.  Real economics needs to reflect real decisions: a response to Johnson.

Authors:  Mark Sculpher; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Points to consider in assessing and appraising predictive genetic tests.

Authors:  Wolf H Rogowski; Scott D Grosse; Jürgen John; Helena Kääriäinen; Alastair Kent; Ulf Kristofferson; Jörg Schmidtke
Journal:  J Community Genet       Date:  2010-10-16

3.  Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context.

Authors:  Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Exploring a new method for deriving the monetary value of a QALY.

Authors:  Carl Tilling; Marieke Krol; Arthur E Attema; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2015-08-20

Review 5.  Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

Review 6.  Using the stated preference technique for eliciting valuations: the role of the payment vehicle.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

7.  Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?

Authors:  Wolf H Rogowski; Scott D Grosse; Jörg Schmidtke; Georg Marckmann
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

8.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

Review 9.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Outcome measurement in economic evaluations of public health interventions: a role for the capability approach?

Authors:  Paula K Lorgelly; Kenny D Lawson; Elisabeth A L Fenwick; Andrew H Briggs
Journal:  Int J Environ Res Public Health       Date:  2010-05-06       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.